secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001658247-26-000020
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics' Chief Development and Operating Officer resigns effective April 10, 2026
--------------------------------------------------------------------------------

- Jeff Knight resigns as Chief Development and Operating Officer, effective April 10, 2026.
- Resignation is to pursue another opportunity; not related to any disagreement with the Company.
- No successor named; Knight's duties and direct reports reassigned to other executive leadership team members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000165824726000020/0001658247-26-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000165824726000020/crnx-20260317.htm
  HTML page:      https://secwatch.observer/filing/0001658247-26-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer